View ValuationStem Cells Spin 将来の成長Future 基準チェック /06現在、 Stem Cells Spinの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長22.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • May 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł86k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł86k free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 52% per year over the past 5 years. Revenue is less than US$1m (zł66k revenue, or US$18k). Market cap is less than US$10m (zł16.5m market cap, or US$4.52m).お知らせ • Nov 12Stem Cells Spin S.A. to Report Q3, 2025 Results on Nov 14, 2025Stem Cells Spin S.A. announced that they will report Q3, 2025 results on Nov 14, 2025New Risk • May 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 19% per year over the past 5 years. Revenue is less than US$1m (zł58k revenue, or US$15k). Market cap is less than US$10m (zł7.77m market cap, or US$2.07m). Minor Risk Less than 1 year of cash runway based on current free cash flow (-zł71k).Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Net loss: zł133.5k (loss widened 3.9% from 1Q 2024).New Risk • Mar 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 0.5% per year over the past 5 years. Revenue is less than US$1m (zł54k revenue, or US$14k). Market cap is less than US$10m (zł7.44m market cap, or US$1.94m). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).New Risk • Feb 21New major risk - Revenue and earnings growthEarnings have declined by 0.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 0.5% per year over the past 5 years. Revenue is less than US$1m (zł54k revenue, or US$14k). Market cap is less than US$10m (zł8.76m market cap, or US$2.20m).Reported Earnings • Aug 18Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: zł130.7k (down zł148.8k from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.お知らせ • Jun 05Stem Cells Spin S.A., Annual General Meeting, Jun 27, 2024Stem Cells Spin S.A., Annual General Meeting, Jun 27, 2024.Reported Earnings • May 20First quarter 2024 earnings releasedFirst quarter 2024 results: Net loss: zł128.5k (loss widened 64% from 1Q 2023).Reported Earnings • Feb 16Full year 2023 earnings released: zł0.004 loss per share (vs zł0.001 profit in FY 2022)Full year 2023 results: zł0.004 loss per share (down from zł0.001 profit in FY 2022). Net loss: zł154.0k (down zł180.6k from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance.お知らせ • Jan 23+ 4 more updatesStem Cells Spin S.A. to Report Fiscal Year 2023 Final Results on Apr 30, 2024Stem Cells Spin S.A. announced that they will report fiscal year 2023 final results on Apr 30, 2024Buy Or Sell Opportunity • Jan 22Now 20% undervaluedOver the last 90 days, the stock has risen 22% to zł0.43. The fair value is estimated to be zł0.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.6% over the last 3 years. Earnings per share has declined by 41%.Reported Earnings • Nov 19Third quarter 2023 earnings releasedThird quarter 2023 results: Net loss: zł99.8k (loss widened 51% from 3Q 2022).Reported Earnings • Aug 20Second quarter 2023 earnings releasedSecond quarter 2023 results: Net income: zł18.1k (up zł118.4k from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.お知らせ • Jun 04Stem Cells Spin S.A., Annual General Meeting, Jun 29, 2023Stem Cells Spin S.A., Annual General Meeting, Jun 29, 2023, at 09:00 Central European Standard Time.Reported Earnings • May 21First quarter 2023 earnings releasedFirst quarter 2023 results: Net loss: zł78.4k (down 147% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 18Full year 2022 earnings released: EPS: zł0.001 (vs zł0.003 loss in FY 2021)Full year 2022 results: EPS: zł0.001 (up from zł0.003 loss in FY 2021). Revenue: zł248.4k (down 53% from FY 2021). Net income: zł26.7k (up zł154.1k from FY 2021). Profit margin: 11% (up from net loss in FY 2021). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.お知らせ • Jan 31+ 4 more updatesStem Cells Spin S.A. to Report Fiscal Year 2022 Results on May 31, 2023Stem Cells Spin S.A. announced that they will report fiscal year 2022 results on May 31, 2023お知らせ • Jun 07Stem Cells Spin S.A., Annual General Meeting, Jun 28, 2022Stem Cells Spin S.A., Annual General Meeting, Jun 28, 2022, at 10:00 Central European Standard Time.Reported Earnings • May 22First quarter 2022 earnings releasedFirst quarter 2022 results: Net income: zł167.4k (down 2.2% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 16Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: zł0.002 loss per share (down from zł0 in FY 2020). Net loss: zł99.5k (down zł105.9k from profit in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 02+ 3 more updatesStem Cells Spin S.A. to Report Q4, 2022 Results on Feb 14, 2022Stem Cells Spin S.A. announced that they will report Q4, 2022 results on Feb 14, 2022Reported Earnings • May 23First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: zł234.6k (up zł215.6k from 1Q 2020). Net income: zł171.2k (up zł261.9k from 1Q 2020). Profit margin: 73% (up from net loss in 1Q 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Mar 09New 90-day low: zł1.13The company is down 25% from its price of zł1.50 on 09 December 2020. The Polish market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period.Reported Earnings • Feb 18Full year 2020 earnings released: zł0.001 loss per share (vs zł0.017 loss in FY 2019)Full year 2020 results: Net loss: zł51.3k (loss narrowed 93% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings.お知らせ • Feb 02Stem Cells Spin S.A. to Report Fiscal Year 2020 Final Results on May 31, 2021Stem Cells Spin S.A. announced that they will report fiscal year 2020 final results on May 31, 2021お知らせ • Feb 01+ 3 more updatesStem Cells Spin S.A. to Report Q3, 2021 Results on Nov 15, 2021Stem Cells Spin S.A. announced that they will report Q3, 2021 results on Nov 15, 2021Is New 90 Day High Low • Dec 10New 90-day high: zł1.88The company is up 32% from its price of zł1.42 on 11 September 2020. The Polish market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period.Is New 90 Day High Low • Sep 29New 90-day high: zł1.70The company is up 75% from its price of zł0.97 on 26 June 2020. The Polish market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 62% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Stem Cells Spin は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測WSE:SCS - アナリストの将来予測と過去の財務データ ( )PLN Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20250-103N/A6/30/20250-103N/A3/31/20250-103N/A12/31/20240-103N/A9/30/20240000N/A6/30/20240000N/A3/31/20240000N/A12/31/20230000N/A9/30/20230000N/A6/30/20230001N/A3/31/20230000N/A12/31/202200-1-1N/A9/30/20220000N/A6/30/20220000N/A3/31/20220011N/A12/31/20211011N/A9/30/20211000N/A6/30/20210011N/A3/31/20210000N/A12/31/20200000N/A9/30/20200000N/A6/30/20200000N/A3/31/20201-100N/A12/31/20191-100N/A9/30/20191-100N/A6/30/20190-1N/A0N/A3/31/20190-1N/A10N/A12/31/20181-1N/A10N/A9/30/201810N/A10N/A6/30/201810N/A10N/A3/31/201810N/A0N/A12/31/201700N/A0N/A9/30/201710N/A0N/A6/30/201710N/A0N/A3/31/201710N/A1N/A12/31/201610N/A-1N/A9/30/201611N/A-7N/A6/30/201621N/A1N/A3/31/201621N/A-1N/A12/31/201521N/A1N/A9/30/201510N/A10N/A6/30/201500N/A1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SCSの予測収益成長が 貯蓄率 ( 5.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: SCSの収益がPolish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: SCSの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: SCSの収益がPolish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: SCSの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SCSの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 22:26終値2026/05/22 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Stem Cells Spin S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • May 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł86k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł86k free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 52% per year over the past 5 years. Revenue is less than US$1m (zł66k revenue, or US$18k). Market cap is less than US$10m (zł16.5m market cap, or US$4.52m).
お知らせ • Nov 12Stem Cells Spin S.A. to Report Q3, 2025 Results on Nov 14, 2025Stem Cells Spin S.A. announced that they will report Q3, 2025 results on Nov 14, 2025
New Risk • May 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 19% per year over the past 5 years. Revenue is less than US$1m (zł58k revenue, or US$15k). Market cap is less than US$10m (zł7.77m market cap, or US$2.07m). Minor Risk Less than 1 year of cash runway based on current free cash flow (-zł71k).
Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Net loss: zł133.5k (loss widened 3.9% from 1Q 2024).
New Risk • Mar 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 0.5% per year over the past 5 years. Revenue is less than US$1m (zł54k revenue, or US$14k). Market cap is less than US$10m (zł7.44m market cap, or US$1.94m). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).
New Risk • Feb 21New major risk - Revenue and earnings growthEarnings have declined by 0.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 0.5% per year over the past 5 years. Revenue is less than US$1m (zł54k revenue, or US$14k). Market cap is less than US$10m (zł8.76m market cap, or US$2.20m).
Reported Earnings • Aug 18Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: zł130.7k (down zł148.8k from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.
お知らせ • Jun 05Stem Cells Spin S.A., Annual General Meeting, Jun 27, 2024Stem Cells Spin S.A., Annual General Meeting, Jun 27, 2024.
Reported Earnings • May 20First quarter 2024 earnings releasedFirst quarter 2024 results: Net loss: zł128.5k (loss widened 64% from 1Q 2023).
Reported Earnings • Feb 16Full year 2023 earnings released: zł0.004 loss per share (vs zł0.001 profit in FY 2022)Full year 2023 results: zł0.004 loss per share (down from zł0.001 profit in FY 2022). Net loss: zł154.0k (down zł180.6k from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance.
お知らせ • Jan 23+ 4 more updatesStem Cells Spin S.A. to Report Fiscal Year 2023 Final Results on Apr 30, 2024Stem Cells Spin S.A. announced that they will report fiscal year 2023 final results on Apr 30, 2024
Buy Or Sell Opportunity • Jan 22Now 20% undervaluedOver the last 90 days, the stock has risen 22% to zł0.43. The fair value is estimated to be zł0.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.6% over the last 3 years. Earnings per share has declined by 41%.
Reported Earnings • Nov 19Third quarter 2023 earnings releasedThird quarter 2023 results: Net loss: zł99.8k (loss widened 51% from 3Q 2022).
Reported Earnings • Aug 20Second quarter 2023 earnings releasedSecond quarter 2023 results: Net income: zł18.1k (up zł118.4k from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.
お知らせ • Jun 04Stem Cells Spin S.A., Annual General Meeting, Jun 29, 2023Stem Cells Spin S.A., Annual General Meeting, Jun 29, 2023, at 09:00 Central European Standard Time.
Reported Earnings • May 21First quarter 2023 earnings releasedFirst quarter 2023 results: Net loss: zł78.4k (down 147% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 18Full year 2022 earnings released: EPS: zł0.001 (vs zł0.003 loss in FY 2021)Full year 2022 results: EPS: zł0.001 (up from zł0.003 loss in FY 2021). Revenue: zł248.4k (down 53% from FY 2021). Net income: zł26.7k (up zł154.1k from FY 2021). Profit margin: 11% (up from net loss in FY 2021). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
お知らせ • Jan 31+ 4 more updatesStem Cells Spin S.A. to Report Fiscal Year 2022 Results on May 31, 2023Stem Cells Spin S.A. announced that they will report fiscal year 2022 results on May 31, 2023
お知らせ • Jun 07Stem Cells Spin S.A., Annual General Meeting, Jun 28, 2022Stem Cells Spin S.A., Annual General Meeting, Jun 28, 2022, at 10:00 Central European Standard Time.
Reported Earnings • May 22First quarter 2022 earnings releasedFirst quarter 2022 results: Net income: zł167.4k (down 2.2% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 16Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: zł0.002 loss per share (down from zł0 in FY 2020). Net loss: zł99.5k (down zł105.9k from profit in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 02+ 3 more updatesStem Cells Spin S.A. to Report Q4, 2022 Results on Feb 14, 2022Stem Cells Spin S.A. announced that they will report Q4, 2022 results on Feb 14, 2022
Reported Earnings • May 23First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: zł234.6k (up zł215.6k from 1Q 2020). Net income: zł171.2k (up zł261.9k from 1Q 2020). Profit margin: 73% (up from net loss in 1Q 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Mar 09New 90-day low: zł1.13The company is down 25% from its price of zł1.50 on 09 December 2020. The Polish market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period.
Reported Earnings • Feb 18Full year 2020 earnings released: zł0.001 loss per share (vs zł0.017 loss in FY 2019)Full year 2020 results: Net loss: zł51.3k (loss narrowed 93% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings.
お知らせ • Feb 02Stem Cells Spin S.A. to Report Fiscal Year 2020 Final Results on May 31, 2021Stem Cells Spin S.A. announced that they will report fiscal year 2020 final results on May 31, 2021
お知らせ • Feb 01+ 3 more updatesStem Cells Spin S.A. to Report Q3, 2021 Results on Nov 15, 2021Stem Cells Spin S.A. announced that they will report Q3, 2021 results on Nov 15, 2021
Is New 90 Day High Low • Dec 10New 90-day high: zł1.88The company is up 32% from its price of zł1.42 on 11 September 2020. The Polish market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Sep 29New 90-day high: zł1.70The company is up 75% from its price of zł0.97 on 26 June 2020. The Polish market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 62% over the same period.